Home Authors Posts by HealthDay.com



Stopping RAS Inhibitors May Worsen Outcomes in CKD

Stopping therapy tied to lower risk for dialysis, but higher risk for cardiovascular events and death

Higher Dietary Fiber Lowers Premenopausal Depression Risk

Significant association between dietary fiber intake and prevalence of depression seen for premenopausal, but not postmenopausal, women

HealthDay Reports: New Coronavirus Strain More Contagious

Stem Cell Infusions Investigated for Treatment of COVID-19 ARDS

Researchers explore possible anti-inflammatory effects of mesenchymal stem cells in COVID-19 acute respiratory distress syndrome

La vacuna de Pfizer contra la COVID parece promisoria

One-Third of U.S. Adults Likely to Refuse a COVID-19 Vaccine

Blacks, women, and conservatives more hesitant in the United States

Age When Starting to Smoke Linked to Risk for CVD Mortality

Smokers More Likely to Report Symptoms Suggestive of COVID-19

Current smokers have increased risk for reporting classic symptoms, more than five symptoms, more than 10 symptoms

TAVR Volumes in the U.S. Have Risen Each Year Since 2011

Referrals for Acute Heart Failure Dropped During COVID-19

Referrals to acute heart failure team decreased; corresponding increase seen in 30-day case fatality rate

Aphasia Affects Brain Similar to Alzheimer's

Memory Preserved in Rare Aphasia Tied to Alzheimer Disease

Decline in language function, but not episodic memory, seen for primary progressive aphasia associated with Alzheimer disease

Repeat Postvasectomy Semen Analyses Down Under New Guidelines

Men in postguideline cohort had lower risk for requiring any repeat postvasectomy semen analysis

Smoking Has Negative Effects for Patients With Psoriasis

Cardiorespiratory Fitness Linked to Psoriasis, Psoriatic Arthritis

Significant association found between low cardiorespiratory fitness at mean age of 18.3 years and psoriasis, psoriatic arthritis among men

Triplet Therapy Slows Refractory Multiple Myeloma

Bupropion-Naltrexone Bests Placebo in Methamphetamine Use Disorder

Response was low but higher with naltrexone-bupropion than placebo during 12-week, two-stage trial